Additional Resources
Societies/Websites
- American College of Chest Physicians. http://www.chestnet.org
- Centers for Disease Control and Prevention. Healthcare professionals. https://www.cdc.gov/asthma/healthcare.html#guidelines
- Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. https://ginasthma.org/wp-content/uploads/2021/05/GINA-Main-Report-2021-V2-WMS.pdf
- National Jewish Health. https://www.nationaljewish.org/conditions/asthma
- National Asthma Education and Prevention Program (NAEPP). https://www.nhlbi.nih.gov/science/national-asthma-education-and-prevention-program-naepp
Articles
- Abonia JP, Putnam PE. Mepolizumab in eosinophilic disorders. Expert Rev Clin Immunol. 2011;7:411-417. doi:10.1586/eci.11.27
- Accordini S, Cappa V, Braggion M, et al. The impact of diagnosed and undiagnosed current asthma in the general adult population. Int Arch Allergy Immunol. 2011;155:403-411. doi:10.1159/000320780
- Apter AJ, Wan F, Reisine S, et al. The association of health literacy with adherence and outcomes in moderate-severe asthma. J Allergy Clin Immunol. 2013;132:321-327. doi:10.1016/j.jaci.2013.02
- Bel EH, Wenzel SE, Thompson PJ, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014;371:1189-1197. doi:10.1056/NEJMoa1403291
- Bjemer L, Lemiere C, Maspero J, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 study. Chest. 2016;150:789-798. doi:10.1016/j.chest.2016.03.032
- Bleecker ER, FitzGerald M, Chanez P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high dosage inhaled corticosteroids and long acting β2 agonists (SIROCCO): a randomised, multicenter, placebo-controlled phase 3 trial. Lancet. 2016;388:2115-2127. doi:10.1016/S0140-6736(16)31324-1
- Boonpiyathat T, Sözener Z, Satitsuksanoa P, et al. Immunologic mechanisms in asthma. Semin Immunol. 2019;46:101333. doi:10.1016/j.smim.2019.101333
- Côté A, Godbout K, Boulet L. The management of severe asthma in 2020. Biochem Pharmacol. 2020;179:114112. doi:10.1016/j.bcp.2020.114112
- Fox Huffaker M, Phipatanakul W. Pediatric asthma: guidelines-based care, omalizumab and other potential biologic agents. Immunol Allergy Clin North Am. 2015;35:129-144. doi:10.1016/j.iac.2014.09.005
- Hanania NA, Noonan M, Corren J, et al. Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies. Thorax. 2015;70:748-756. doi:10.1136/thoraxjnl-2014-206719
- Jarjour NN, Erzurum SC, Bleecker E, et al. Severe asthma: lessons learned from the National Heart, Lung, and Blood Institute Severe Asthma Research Program. Am J Respir Crit Care Med. 2012;185:356-362. doi:10.1164/rccm.201107-1317PP
- Lambrecht BN, Hammad H, Fahy JV. The cytokines of asthma. Immunity. 2019;50:975-991. doi:10.1016/j.immuni.2019.03.018
- Laster N, Holsey CN, Shendell DG, et al. Barriers to asthma management among urban families: caregiver and child perspectives. J Asthma. 2009;46:731-739. doi:10.1080/02770900903082571
- Moore WC, Bleeker ER, Curran-Everett D, et al. Characterization of severe asthma phenotypes by the National Heart, Lung, and Blood Institute Severe Asthma Research Program. J Allergy Clin Immunol. 2007;119:405-413. doi:10.1016/j.jaci.2006.11.639
- Nowak RM, Parker JM, Silverman RA, et al. A randomized trial of benralizumab, an antiinterleukin 5 receptor α monoclonal antibody, after acute asthma. Am J Emerg Med. 2015;33:14-20. doi:10.1016/j.ajem.2014.09.036
- O’Byrne PM, Pedersen S, Schatz M, et al. The poorly explored impact of uncontrolled asthma. Chest. 2013;143:511-523. doi:10.1378/chest.12-0412
- Ortega HG, Liu MC, Pavord ID, et al. Treatment in patients with severe eosinophilic asthma. N Eng J Med. 2014;371:1198-1207. doi:10.1056/NEJMoa1403290
- Rathinam KK, Abraham JJ, Vijayakumar TM. Dupilumab in the treatment of moderate to severe asthma: an evidence-based review. Curr Ther Res Clin Exp. 2019;91:45-51. doi:10.1016/j.curtheres.2019.100571
- Reihman A, Holguin F, Sharma S. Management of severe asthma beyond the guidelines. Curr Allergy Asthma Rep. 2020;20:47. doi:10.1007/s11882-020-00940-6
- Rogliani P, Calzetta L, Matera MG, et al. Severe asthma and biological therapy: when, which, and for whom. Pulm Ther. 2020;6:47-66. doi:10.1007/s41030-019-00109-1
- Russell R, Brightling CE. Anti-IL-5 for severe asthma. Chest. 2016;150:766-768. doi:10.1016/j.chest.2016.06.013
- Sokol KC, Sharma G, Lin YL, et al. Choosing wisely: adherence by physicians to recommended use of spirometry in the diagnosis and management of adult asthma. Am J Med. 2015;128:502-508. doi:10.1016/j.amjmed.2014.12.006
- Tan LD, Bratt JM, Godor D, et al. Benralizumab: a unique IL-5 inhibitor for severe asthma. J Asthma Allergy. 2016;9:71-78. doi:10.2147/JAA.S78049
- Tan R, Liew MF, Lim HF, et al. Promises and challenges of biologics for severe asthma. Biochem Pharmacol. 2020;179:114012. doi:10.1016/j.bcp.2020.114012
- Vatrella A, Fabozzi I, Calabrese C, et al. Dupilumab: a novel treatment for asthma. J Asthma Allergy. 2014;7:123-130. doi:10.2147/JAA.S52387
- Wenzel S, Castro M, Corren J, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high dose inhaled corticosteroids plus a long acting β2 agonist: a randomised double-blind, placebo controlled pivotal phase 2b dose-ranging trial. Lancet. 2016;388:31-44. doi:10.1016/S0140-6736(16)30307-5
- Agache I, Beltran J, Akdis C, et al. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines – recommendations on the use of biologicals in severe asthma. Allergy. 2020;75:1023-1042. doi:10.1111/all.14221